Immunome Clears Key Regulatory Milestone as Lead Drug Goes Under FDA Review

기사 요약

FDA accepts Immunome's varegacestat NDA for desmoid tumors, with an April 28, 2027, PDUFA date backed by positive Phase 3 data.